Funding
EFC is supported by an MRC Clinical Research Training Fellowship
(MR/V028731/1) that funds investigation into the pathogenesis of chronic
histiocytic intervillositis. TM is supported by an MRF fellowship
(MRF-057-0004-RG-MCDO-C0800). DJW is supported by the National Institute
for Health Research University College London Hospitals Biomedical
Research Centre.
For the purpose of open access, the author has applied a Creative
Commons Attribution (CC BY) licence to any Author Accepted Manuscript
version arising.
—————————————————————————————————————-
References
1. Simula NK, Terry J, Kent NE, et al. Chronic Intervillositis of
Unknown Etiology (CIUE): Prevalence, patterns and reproductive outcomes
at a tertiary referral institution. Placenta. 2020;100:60-65.
2. Bos M, Nikkels PGJ, Cohen D, et al. Towards standardized criteria for
diagnosing chronic intervillositis of unknown etiology: A systematic
review. Placenta. 2018;61:80-88.
3. Benachi A, Rabant M, Martinovic J, et al. Chronic histiocytic
intervillositis: manifestation of placental alloantibody-mediated
rejection. Am J Obstet Gynecol. 2021;225(6):662.e1-662.e11
4. Brady CA, Williams C, Batra G, et al. Immunomodulatory Therapy
Reduces the Severity of Placental Lesions in Chronic Histiocytic
Intervillositis. Front Med (Lausanne). 2021;8:753220.
5. Reus AD, van Besouw NM, Molenaar NM, et al. An immunological basis
for chronic histiocytic intervillositis in recurrent fetal loss.Am J Reprod Immunol. 2013;70(3):230-237.
—————————————————————————————————————-